Implantable Bone Conduction Hearing Aids
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical policy governing medical necessity coverage for implantable bone-anchored and transcutaneous bone conduction hearing systems for members of Blue Cross Blue Shield of North Carolina.
No material clinical or coverage changes in this revision.
Coverage Criteria for Implantable Bone Conduction Hearing Systems
Conductive or mixed hearing loss - initial coverage
Covered when ALL of the following are met:
Devices listed with thresholds in policy
Single-sided sensorineural deafness (alternative to AC CROS)
Covered when ALL of the following are met:
When Covered
Covered when ALL of the following are met (policy language describes device-specific audiologic thresholds and medical indications):
Device-specific pure tone average bone-conduction thresholds and age limits (examples and device-specific clarifications per FDA approvals) must be documented
Use of implantable bone-conduction (bone-anchored) hearing aids in individuals with bilateral sensorineural hearing loss and any other indications not specifically listed in the "When Covered" section are considered investigational and are not eligible for coverage.
The BAHA Softband™ application, which uses a headband to couple a sound processor transcutaneously to the skull and contains no implanted components, is not addressed in this policy.
An implantable bone conduction hearing aid is not covered for indications other than those listed in the When Covered section. Devices implanted for indications outside the specified coverage criteria may be denied.
Non‑implantable intraoral bone conduction hearing aids (for example, the SoundBite™ system) are considered investigational and not covered under this policy.
The use of bilateral bone‑anchored hearing aids in patients with bilateral sensorineural hearing loss is considered investigational (not covered) and is excluded from coverage.
Billing, Codes, and Audiologic Thresholds
| L8690 | HCPCS code added Jan 1, 2007 (billing/coding history) |
| L8691 | HCPCS code added Jan 1, 2007 (billing/coding history) |
| 69717 | CPT code added 6/18/07 |
| 69718 | CPT code added 6/18/07 (terminated/removed later per update notes) |
| L8692 | HCPCS code added Jan 1, 2010 |
| L8693 | HCPCS code added Jan 1, 2011 |
| 69710 | CPT code added (policy history 3/29/11) |
| 69711 | CPT code added (policy history 3/29/11) |
| L8694 | HCPCS code added for effective date 1/1/2018 |
| L8625 | HCPCS code added 3/9/18 |
| K240614 | FDA 510(k) reference - Sentio Ti Implant Kit; Sentio 1 Mini (Product Code PFO) |
| K191457 | FDA 510(k) reference - BONEBRIDGE System, BCI 602 Implant Kit |
Provider Actions, Prior Authorization, and Documentation
Medical record review / prior authorization
Prior authorization or a medical necessity determination may be required for implantable bone-conduction hearing aids. BCBSNC may request medical records to determine medical necessity; when records are requested, letters of support/explanation are useful but are not sufficient unless they include all specific information needed for the medical necessity determination.
- Obtain prior authorization per insurer procedures before implantation when applicable.
- Be prepared to submit complete medical records if requested to support medical necessity.
Prior authorization / billing codes
The policy's Billing/Coding section lists multiple CPT and HCPCS codes relevant to implantable bone-conduction devices and has been revised repeatedly; prior authorization and billing should follow current insurer practices and the specific codes listed in the policy.
- Verify and use the current CPT/HCPCS codes listed in the policy (e.g., 69710–69730 series, 92622–92623, L8625, L8690–L8694) when submitting claims.
- Note that codes have been added and removed over time; confirm the active codes at time of billing.
Benefits verification
Review the member's benefit design in the Member's Benefit Booklet to determine availability of benefits prior to applying this medical policy, since member benefits may vary according to benefit design.
- Confirm coverage availability and any age‑specific or frequency limits before scheduling procedures.
Policy position: implantable bone-conduction devices
Implantable bone-conduction devices are positioned as alternatives to air-conduction hearing aids or CROS devices when the patient's age, medical indications, and device-specific audiologic thresholds meet the policy's When Covered criteria.
- Ensure patient meets the When Covered criteria (age thresholds and device-specific pure tone average bone‑conduction limits) before pursuing implantation.
Records upon request — completeness required
BCBSNC may request medical records to determine medical necessity; letters without full specific information are not sufficient documentation unless they include all specific information needed to make the determination.
- Provide complete audiologic and clinical records when responding to a records request; do not rely on unsupported letters of recommendation alone.
Documentation of age and audiologic thresholds
When Covered criteria specify patient age and device‑specific audiologic thresholds (pure tone average bone‑conduction thresholds at 0.5, 1, 2, and 3 kHz and, for single‑sided deafness, AC PTA of the normal ear), those measurements must be documented in the medical record to establish coverage eligibility.
- Document age (e.g., ≥5 years; device-specific older age limits for some systems historically) and device‑specific PTA bone‑conduction thresholds (e.g., ≤45 dB, ≤55 dB, or ≤65 dB depending on device) in the chart.
- For single-sided sensorineural deafness, document the normal ear's AC PTA better than 20 dB at 0.5, 1, 2, and 3 kHz.
Investigational indications and denial risk
Use of implantable bone-conduction devices for indications not listed in the When Covered section — including use in individuals with bilateral sensorineural hearing loss or non‑implantable intraoral devices — is considered investigational and may be denied.
- Do not submit claims or prior authorization requests for bilateral sensorineural hearing loss or intraoral non‑implantable devices under this policy; these indications are investigational.
Coverage restriction — unsupported indications
An implantable bone conduction hearing aid is not covered for indications other than those listed in the When Covered section; use for bilateral sensorineural hearing loss is specifically considered investigational and not covered.
- Confirm the patient's indication matches the When Covered criteria before requesting authorization or submitting claims to avoid denials.
Definitions and Device Types
Background on Bone-Conduction Hearing Systems
Bone‑conduction hearing systems transmit sound by conduction through the skull to the cochlea and are alternatives to air‑conduction hearing aids for patients with conductive, mixed, or single‑sided sensorineural hearing loss. Implantable systems may be percutaneous (abutment) or transcutaneous (magnetic coupling) and rely on osseointegration or implanted magnets for stable coupling between the external sound processor and the inner ear.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.